[Second-line chemotherapy and new drugs for ovarian carcinoma].
Epithelial ovarian carcinoma represents a prototypic example of neoplastic disease sharing at the same time good chemosensitivity as well as marked propensity to relapse. If in one hand the definition of almost clear-cut guidelines has been reached in the setting of first-line therapy (i.e., cytoreductive surgery followed by first-line chemotherapy), more difficult to discern for the oncologist remains the choice of treatment in the occasion(s) of relapse(s). This article focuses on this particular setting of disease, analyzing the specific criteria of choice of drug or their combinations; the definite criteria followed for the use of platinum compounds in the second line of treatment, even if already utilized in the front line therapy, are also analyzed. Specific attention has also been paid in the definition of the role of single parameter as a "prognosticator" and/or as "predictor" of response. The Authors emphasize how clinical definitions remain the more reliable, simple, reproducible tools in therapeutical decision making.
Priolo
D
D
Divisione Oncologia Medica, Ospedale S. Vincenzo, Taormina, Italia. omtaormina@tin.it
Antonelli
G
G
Calì
S
S
Colina
P
P
Giuffrida
D
D
Malaponte
E
E
Mattina
M
M
Parisi
A
A
Sambataro
D
D
Vitale
F
F
Ferraù
F
F
D000970:Antineoplastic Agents / Q000097:blood / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D011379:Prognosis
D000970:Antineoplastic Agents; D018394:CA-125 Antigen